Pemigatinib for the treatment of metastatic or unresctable colorectal cancer - Clinical Trial
What is the Purpose of this Study?
We are doing this study to see if the study drug, pemigatinib, is safe and effective for fighting a specific type of colorectal cancer.
Who Can Participate in the Study?
Adults with colorectal cancer that:
-Is metastatic or unresectable; and
-Contains alterations in the genes FGFR1, FGFR2, or FGFR3
Additionally, eligible participants must have failed prior standard-of-care therapy or not be able to tolerate it.
What is Involved?
If you choose to join this study, you will:
-Take the study drug, pemigatinib, by mouth once per day
-Return to the clinic every 3 weeks so we can monitor your health
-Give blood and urine for testing
-Get CT or MRI scans every 9 weeks
You may be on the study drug for up to 2 years.